Galapagos

🇧🇪Belgium

Country: 🇧🇪Belgium

Ownership: Public

Established: 1999-01-01

Employees: 1.1K

Market Cap: $1.9B

Website: http://www.glpg.com

Introduction: Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.

Clinical Trials

First-in-Human Single and Multiple Dose of GLPG2222

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: GLPG2222 multiple doses
Drug: Placebo multiple doses
Drug: GLPG2222 single dose
Drug: Placebo single dose

First Posted Date: 2016-01-25

Last Posted Date: 2016-07-29

Lead Sponsor: Galapagos NV

Target Recruit Count: 40

Registration Number: NCT02662452

Locations: 🇧🇪
SGS LSS Clinical Pharmacology Unit Antwerp, Antwerp, Belgium

A Drug-drug Interaction Study Between GLPG1205 and a Cocktail of CYP450 Substrates in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: GLPG1205
Drug: Cocktail of CYP450 substrates

First Posted Date: 2015-12-07

Last Posted Date: 2016-02-23

Lead Sponsor: Galapagos NV

Target Recruit Count: 14

Registration Number: NCT02623296

Locations: 🇧🇪
SGS LSS Clinical Pharmacology Unit Antwerp, Antwerp, Belgium

First-in-Human Single and Multiple Dose of GLPG1972

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: GLPG1972 single ascending doses
Drug: Placebo single dose
Drug: GLPG1972 multiple ascending doses
Drug: Placebo multiple doses

First Posted Date: 2015-11-23

Last Posted Date: 2016-07-29

Lead Sponsor: Galapagos NV

Target Recruit Count: 41

Registration Number: NCT02612246

Locations: 🇧🇪
SGS LSS Clinical Pharmacology Unit Antwerp, Antwerp, Belgium

Oral Bioavailability of Solid Formulation of GLPG1837 With and Without Food

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: 500 mg GLPG1837 as oral suspension
Drug: 500 mg GLPG1837 as oral tablet

First Posted Date: 2015-09-29

Last Posted Date: 2015-10-23

Lead Sponsor: Galapagos NV

Target Recruit Count: 12

Registration Number: NCT02562859

Locations: 🇧🇪
SGS LSS Clinical Pharmacology Unit Antwerp, Antwerp, Belgium

A Phase I, Open Interaction Study Between GLPG1837 and Midazolam in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: GLPG1837 500 mg
Drug: Midazolam
Drug: GLPG1837 1000 mg

First Posted Date: 2015-09-29

Last Posted Date: 2015-10-23

Lead Sponsor: Galapagos NV

Target Recruit Count: 24

Registration Number: NCT02562950

Locations: 🇧🇪
SGS LSS Clinical Pharmacology Unit Antwerp, Antwerp, Belgium

Efficacy and Safety of GLPG1205 in Subjects With Active Ulcerative Colitis

Phase 2

Completed

Conditions: Ulcerative Colitis

Interventions: Drug: GLPG1205
Drug: Placebo

First Posted Date: 2015-01-13

Last Posted Date: 2015-11-20

Lead Sponsor: Galapagos NV

Target Recruit Count: 64

Registration Number: NCT02337608

Locations: 🇵🇱
Saint Family Hospital Medical Center, Lodz, Poland
🇨🇿
Orlickoustecka Hospital, Inc., Usti nad Orlici, Czech Republic
🇵🇱
Healthcare Center Orkan Med Stec Michalska Spolka Jawna, Ksawerow, Poland

and more 36 locations

First-in-Human Single and Multiple Dose of GLPG1837

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo single dose
Drug: GLPG1837 single ascending doses
Drug: GLPG1837 multiple ascending doses
Drug: Placebo multiple doses

First Posted Date: 2014-12-24

Last Posted Date: 2015-09-09

Lead Sponsor: Galapagos NV

Target Recruit Count: 64

Registration Number: NCT02325037

Locations: 🇧🇪
SGS LSS Clinical Pharmacology Unit Antwerp, Antwerp, Belgium

First-in-Human Single and Multiple Dose of GLPG1690

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: GLPG1690 single ascending doses
Drug: GLPG1690, multiple ascending doses, oral suspension
Drug: Placebo, multiple ascending doses, oral suspension
Drug: Placebo single ascending doses

First Posted Date: 2014-07-01

Last Posted Date: 2015-09-22

Lead Sponsor: Galapagos NV

Target Recruit Count: 40

Registration Number: NCT02179502

Locations: 🇧🇪
SGS LSS Clinical Pharmacology Unit Antwerp, Antwerp, Belgium

Multiple Ascending Dose Study of GLPG0634 in Japanese and Caucasian Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: GLPG0634 50 mg
Drug: Placebo
Drug: GLPG0634 100 mg
Drug: GLPG0634 200 mg

First Posted Date: 2014-06-12

Last Posted Date: 2014-09-16

Lead Sponsor: Galapagos NV

Target Recruit Count: 36

Registration Number: NCT02162355

Locations: 🇬🇧
Hammersmith Medicines Research (HMR), London, United Kingdom

Oral Bioavailability of Solid Formulation of GLPG1205 With and Without Food

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: 100 mg GLPG1205

First Posted Date: 2014-05-21

Last Posted Date: 2014-07-22

Lead Sponsor: Galapagos NV

Target Recruit Count: 12

Registration Number: NCT02143856

Locations: 🇧🇪
SGS LSS Clinical Pharmacology Unit Antwerp, Antwerp, Belgium

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy